Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Reports Q2 2026 Financial Results and Key Program Updates
Summary
Ionis Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, showing increased revenue and updates on key programs. The company reported total revenue of $268 million for Q2 2026, with commercial revenue of $119 million and research and development revenue of $149 million. Ionis also provided updates on new product launches, including the approval and launch of TRYNGOLZA in the U.S. and the EU, and the launch of DAWNZERA in the EU. Additionally, the company announced the completion of enrollment in the Phase 3 REVEAL trial for obudanersen in Angelman syndrome and the initiation of a Phase 2 study for ION775 in sHTG. Regulatory milestones included the submission of a New Drug Application for zilganersen in Alexander disease and the global launch of bepirovirsen for chronic hepatitis B.
Profitelligence Alerts
Get alerts for IONS
Be first to know when Ionis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Official SEC Documents
Advertisement